Search

Your search keyword '"Sabattini, S"' showing total 237 results
Start Over Author "Sabattini, S"
237 results on '"Sabattini, S"'

12. A phase 2, single-arm, open-label clinical trial on adjuvant active immunotherapy in dogs with appendicular osteosarcoma undergoing amputation and chemotherapy

Author

Marconato L, Melacarne A, Aralla M, Tiraboschi L, Sabattini S, Zeira O, Balboni A, Pisoni L, Guerra D, Faroni E, Rescigno M., and Marconato L, Melacarne A, Aralla M, Tiraboschi L, Sabattini S, Zeira O, Balboni A, Pisoni L, Guerra D, Faroni E, Rescigno M.

Subjects
clinical trial, adjuvant active immunotherapy, dog, osteosarcoma
Published
2021

16. Feline large granular lymphocyte lymphoma: An Italian Society of Veterinary Oncology (SIONCOV) retrospective study

Author

Finotello, R, Vasconi, ME, Sabattini, S, Agnoli, C, Giacoboni, C, Annoni, M, Dentini, A, Bettini, G, Guazzi, P, Stefanello, D, Bottero, E, Mesto, P, Marinelli, R, De Feo, C, Marconato, L, Finotello, R., Vasconi, M.E., Sabattini, S., Agnoli, C., Giacoboni, C., Annoni, M., Dentini, A., Bettini, G., Guazzi, P., Stefanello, D., Bottero, E., Mesto, P., Marinelli, R., De Feo, C., and Marconato, L.

Subjects
Male, Lymphoma, Prognosi, Large granular lymphocyte, Cat Diseases, Prognosis, LGL, Survival Analysis, Feline, Cats, Animals, Veterinary (all), Female, Retrospective Studies
Abstract

Feline large granular lymphocyte (LGL) lymphoma is an uncommon subtype of lymphoma characterized by a grave prognosis and scarce response to chemotherapy. There are limited reports on clinico-pathological and prognostic factors. One-hundred and 9 cats with newly diagnosed LGL lymphoma that underwent initial staging (including hematology, serum biochemistry, thoracic radiographs and abdominal ultrasound), and followed-up were retrospectively evaluated. LGL lymphoma was localized within the gastrointestinal tract with or without extra-intestinal involvement in 91.7% of the cases, and at extra-gastrointestinal sites in 8.3%. Symptoms were frequent. Anemia (31.2%) and neutrophilia (26.6%) were commonly observed, and 14 (12.8%) cats had neoplastic circulating cells. Frequent biochemistry abnormalities included elevated ALT (39.4%) and hypoalbuminemia (28.4%). Twenty (54.1%) of 37 cats had elevated serum LDH. Treatment varied among cats, and included surgery (11%), chemotherapy (23%), corticosteroids (38.5%) and no treatment (27.5%). Median time to progression (MTTP) was 5 days, and median survival time (MST) 21 days. MST was significantly shorter in the case of substage b, circulating neoplastic cells, lack of chemotherapy administration, and lack of treatment response. A small subset of cats (7.3%) survived more than 6 months, suggesting that a more favorable clinical course can be found among LGL lymphoma patients.

Published
2018

17. Therapeutic impact of regional lymphadenectomy in canine stage II cutaneous mast cell tumors

Author

Marconato L, Polton G, Stefanello D, Morello E, Henriques J, Tortorella G, Vasconi ME, Sabattini S., and Marconato L, Polton G, Stefanello D, Morello E, Henriques J, Tortorella G, Vasconi ME, Sabattini S.

Subjects
mast cell tumor, dog, lymphadenectomy, stage II, prognosis
Abstract

Lymph node (LN) metastasis in canine cutaneous mast cell tumours (cMCTs) is a well-known negative prognostic factor. The role of lymphadenectomy in the treatment of stage II disease remains controversial because of its uncertain therapeutic benefit. Aim of this retrospective study was to investigate the impact of lymphadenectomy on tumour control and survival for dogs with stage II cMCTs. Dogs with firstly occurring, histologically confirmed cMCT with LN metastasis undergoing resection of the primary tumour and medical treatment thereafter were retrospectively enrolled. Dogs were classified into two groups: LN sampling (LNS; diagnosis of metastasis obtained by cytology) and regional LN dissection (LND; diagnosis obtained by histopathology). To determine the therapeutic value of lymphadenectomy, the characteristics of recurrence (local, nodal and distant) and survival were compared between groups. Evaluated outcome variables included signalment, anatomic location, diameter, ulceration, substage, surgical margins, Patnaik grading, Kiupel grading and medical treatment. Overall, 152 dogs were included: 81 underwent LND as part of primary surgery and 71 LNS. The median follow-up time was 409 days for LND group and 620 days for LNS group. On univariable analysis, the risk of developing local, nodal or distant relapse was significantly higher in the LNS group compared with LND (P < 0.001). On multivariable analysis, the risk of tumour progression and tumour-related death were 5.47 and 3.61 times higher in the LNS group, respectively (P < 0.001). Regional lymphadenectomy may have therapeutic value and improve prognosis in dogs with stage II cMCTs undergoing surgical removal of the primary tumour and medical treatment.

Published
2018

24. Comparison of two radiation protocols for feline injection site sarcoma

Author

Rossi F, Marconato L, Sabattini S, Cancedda S, Laganga P, Leone V, Rohrer Bley C., and Rossi F, Marconato L, Sabattini S, Cancedda S, Laganga P, Leone V, Rohrer Bley C.

Subjects
radiation therapy, cat, injection site sarcoma, injection site sarcoma, feline, radiation therapy
Published
2015

29. Clinical relevance of simultaneous histopathological grading of canine cutaneous mast cell tumors at first presentation: a retrospective study on 386 cases

Author

Ferrari R, Buracco P, Stefanello D, Sabattini S, Finotello R, Giudice C, Grieco V, Iussich S, Scase T, DI PALMA, STEFANO, Bettini G, Martano M, Marconato L., and Ferrari R, Buracco P, Stefanello D, Sabattini S, Finotello R, Giudice C, Grieco V, Iussich S, Scase T, Di Palma S, Bettini G, Martano M, Marconato L.

Subjects
mast cell tumor, staging, histologic grading, prognosis, dog
Published
2014

31. Feline large granular lymphocyte lymphoma: An Italian Society of Veterinary Oncology (SIONCOV) retrospective study

Author

Finotello, R., primary, Vasconi, M. E., additional, Sabattini, S., additional, Agnoli, C., additional, Giacoboni, C., additional, Annoni, M., additional, Dentini, A., additional, Bettini, G., additional, Guazzi, P., additional, Stefanello, D., additional, Bottero, E., additional, Mesto, P., additional, Marinelli, R., additional, De Feo, C., additional, and Marconato, L., additional

Published
2017
Full Text
View/download PDF

43. A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma.

Author

Finotello, R., Henriques, J., Sabattini, S., Stefanello, D., Felisberto, R., Pizzoni, S., Ferrari, R., and Marconato, L.

Subjects
ANIMAL models of cancer, CANCER chemotherapy, DOXORUBICIN, SURVIVAL analysis (Biometry), METASTASIS
Abstract

Haemangiosarcoma ( HSA) has an aggressive biological behaviour and carries a poor prognosis, with less than 10% of treated dogs surviving longer than 1 year. In this retrospective study a varied metronomic chemotherapy ( MC) regimen preceded by adjuvant doxorubicin-based maximum-tolerated dose chemotherapy ( MTDC) was compared with MTDC, in terms of efficacy [time to metastasis, ( TTM) and survival time ( ST)] and safety in dogs with biologically aggressive HSA. Dogs were eligible if they had no metastasis after MTDC and received either no further chemotherapy or MC maintenance. Twelve dogs received MTDC, and 10 received MC thereafter. Median TTM and ST were significantly longer for dogs receiving MTDC-MC (not reached versus 150 days, P = 0.028; and not reached versus 168 days, P = 0.030, respectively). Treatment was well tolerated. MTDC followed by MC is safe and suggests improved TTM and ST in dogs with surgically removed, biologically aggressive HSA that are treated in the microscopic setting. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

44. Treatment of oral squamous cell carcinoma in a horse by surgical debulking followed by metronomic chemotherapy.

Author

Tornago, R., Sabattini, S., De Simoi, A., Bettini, G., Furlanello, T., Baldassarre, V., Cornali, M., Mazzucato, M., Carlin, S., and Gentilini, F.

Subjects
*TREATMENT of oral cancer, *SQUAMOUS cell carcinoma, *HORSE diseases, *CANCER chemotherapy, *ANTINEOPLASTIC agents
Abstract

A 19-year-old Quarter Horse gelding presented with a 6-week history of hypersalivation, halitosis and dysmasesis. Oral examination revealed retention of food and saliva and the presence of a raised, nodular, 6 × 7 cm, ulcerated mass on the dorsal surface of the tongue base. The mass was confirmed histologically as squamous cell carcinoma. Complete resection of the mass was not possible and surgical laser debulking was followed 15 days later by chemotherapy with a combination of meloxicam and cyclophosphamide in metronomic regimen. After one week, there was a significant improvement in clinical signs and food consumption returned to normal. Therapy was well tolerated with no alteration in haematological or urinalysis parameters. After 5 months of excellent life quality, the horse showed progressive difficulties in mastication and swallowing. Endoscopic examination showed extension of the tumour to all the aboral aspect of the tongue and, with the owner's consent, the patient was subjected to euthanasia. This is believed to be the first report on the combined use of meloxicam and cyclophosphamide in a metronomic fashion for management of an oral squamous cell carcinoma in a horse. Since metronomic therapy is less expensive than conventional chemotherapy, easily administrable and well tolerated, it should be considered as a possible treatment option for nonresectable equine malignant tumours. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results